Stefan Symeonides/cancer.ed.ac.uk
Dec 11, 2024, 10:27
Two new oral ICIs in solid tumors showcasing improved ease of use compared with antibodies – ESMO
ESMO – Eur. Oncology shared an article by Stefan Symeonides on X:
“Early-phase trials presented at ESMOAsia24 report the potential for two new oral small-molecule ICIs in Solid Tumours showcasing favourable benefit-risk profiles and improved ease of use compared w/ antibodies.”
Two oral immune checkpoint inhibitors show preliminary efficacy and manageable safety in early trials.
Authors: Stefan Symeonides, et al.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18